惯性聚合 高效追踪和阅读你感兴趣的博客、新闻、科技资讯
阅读原文 在惯性聚合中打开

推荐订阅源

C
Check Point Blog
J
Java Code Geeks
H
Hackread – Cybersecurity News, Data Breaches, AI and More
D
Docker
腾讯CDC
The GitHub Blog
The GitHub Blog
大猫的无限游戏
大猫的无限游戏
Microsoft Security Blog
Microsoft Security Blog
GbyAI
GbyAI
Stack Overflow Blog
Stack Overflow Blog
博客园 - 司徒正美
T
The Blog of Author Tim Ferriss
Vercel News
Vercel News
P
Proofpoint News Feed
雷峰网
雷峰网
博客园_首页
B
Blog RSS Feed
Microsoft Azure Blog
Microsoft Azure Blog
爱范儿
爱范儿
V
V2EX
F
Fortinet All Blogs
酷 壳 – CoolShell
酷 壳 – CoolShell
MyScale Blog
MyScale Blog
S
SegmentFault 最新的问题

All Articles on Seeking Alpha

All Eyes On Cencora, A Healthcare Supplier That Could See Lots More Upside Simply Good Foods Doesn't Look Like A Growth Stock Anymore Applied Digital: Post-Earnings Clarity Confirms An Accelerated Path To $1 Billion NOI Target IBIT: Why I Stepped To The Side (Technical Analysis) (Rating Downgrade) XES: Oil Service Stocks Turn Pricey; Why It's Time To Take Profits (Rating Downgrade) The Only Dividend Strategy I'd Trust In A 3.5% Fed Funds World Opera: AI-Driven Advertising Prospects - Upside Potential And Rich Dividend Yields RenaissanceRe: Preferred Stock Hasn't Been This Appealing In Years Q1 Earnings Kick Off With Major Banks' Results: Bank of America, Netflix In Focus Sezzle: Consolidation Completed, Re-Rating Ahead Bitmine Immersion Q2 Preview: Ethereum Thesis Facing Important Report Card I Am Sharing 2 Of My Retirement High-Yield Gems The Software Narrative Is Leaking Badly Again Thanks To Anthropic Mythos The Muni Market Looks Appealing In Q2 AVIV: Should Keep Rising If The Ceasefire Holds Foundayo Explained: Lilly's New Weight Loss Pill And The Amazon Effect Sabesp: A New Privatization As An Opportunity! EchoStar: Potential Bull Trap At Play - Take Gains Off The Table Teladoc Health: Improving Fundamentals Support A Turnaround Story March CPI Inflation: 5 Reasons To Stay Calm Two 12%+ Yielding BDC Bargains (One Is My Top Deep-Value Pick) TechnipFMC: We Prefer Saipem With More Room To Improve Tesla: From Bye-Bye To Buy-Buy (Rating Upgrade) DMB: Vulnerable To High Interest Rates Western Midstream: A 9% Yield That Still Grows In A Downturn IQQQ: Tax-Efficient Income From The Nasdaq But Does Not Protect Against Declines Qualys Share Price Pulled Down By Potential Cybersecurity Disruptor S&P 500: A Dead Money Era May Be Here. How To Thrive In It Vistance Networks Looks Better Than Before With Powerful Earnings Growth Commerce Bancshares: Valuation, Not Quality, Is The Problem
Revolution Medicines, Inc. (RVMD) Q1 2026 Earnings Call T...
2026-05-07 · via All Articles on Seeking Alpha

Revolution Medicines, Inc. (RVMD) Q1 2026 Earnings Call May 6, 2026 4:30 PM EDT

Company Participants

Ryan Asay - Senior Vice President of Corporate Affairs
Mark Goldsmith - CEO, President & Chairman
Alan Bart Sandler - Chief Development Officer
Jack Anders - Chief Financial Officer
Wei Lin - Chief Medical Officer
Stephen Kelsey - President of Research & Development
Anthony Mancini - Chief Global Commercialization Officer

Conference Call Participants

Cory Kasimov - Evercore ISI Institutional Equities, Research Division
Yue-Wen Zhu - LifeSci Capital, LLC, Research Division
Michael Schmidt - Guggenheim Securities, LLC, Research Division
Faisal Khurshid - Jefferies LLC, Research Division
Lut Ming Cheng - JPMorgan Chase & Co, Research Division
Marc Frahm - TD Cowen, Research Division
Jonathan Chang - Leerink Partners LLC, Research Division
Michael Yee - UBS Investment Bank, Research Division
Laura Prendergast - Stifel, Nicolaus & Company, Incorporated, Research Division
Jay Olson - Oppenheimer & Co. Inc., Research Division
Kelsey Goodwin - Piper Sandler & Co., Research Division
Kalpit Patel - Wolfe Research, LLC
Alec Stranahan - BofA Securities, Research Division

Presentation

Operator

Good day, and thank you for standing by. Welcome to the Revolution Medicines Q1 2026 Earnings Call. [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to hand it over to Ryan Asay, Senior VP of Corporate Affairs. Ryan, you have the floor.

Ryan Asay
Senior Vice President of Corporate Affairs

Thank you, operator, and welcome, everyone, to the First Quarter 2026 Earnings Call. Joining me on today's call are Dr. Mark Goldsmith, Revolution Medicines' Chairman and Chief Executive Officer; Dr. Alan Sandler, our Chief Development Officer; and Jack Anders, our Chief Financial Officer. Dr. Steve Kelsey, our President of R&D; Dr. Wei Lin, our Chief Medical Officer; and Anthony Mancini, our Chief Global Commercialization Officer will join us for the Q&A portion of today's call.

We would like to inform you that